17 results about "Renal Cell Cancers" patented technology

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

The application discloses a kind of kidney cell cancer patient prognosis risk prediction methods based on multi-modal deep learning.The present application processes whole field digital pathology section (WSI) image and pathological diagnosis report by deep learning algorithm, extracts text features using natural language processing model, extracts image features using computer vision model and ABMIL network, and carries out multi-modal feature fusion through Cross-attention Transformer network, and finally outputs the survival risk curve of patient changes with time in combination with Weibull survival function, for assisting doctor to carry out more accurate prognosis evaluation and survival analysis.

The invention discloses a renal cell carcinoma circulating tumor cell culture medium as well as a culture method and application thereof. The invention belongs to the field of biological medicine, and particularly relates to a renal cell carcinoma circulating tumor cell culture medium and a culture method and application. The invention provides a composition for culturing circulating tumor cells, the composition contains a cell culture medium and a biological scaffold, the cell culture medium contains a reagent named as RFGI, and the RFGI contains fetal calf serum, insulin, glucose and R-spondin-1 protein. Enriching the isolated circulating tumor cells through density gradient centrifugation; the composition is used for culturing the enriched circulating tumor cells to obtain the circulating tumor cells, so that the survival rate of the circulating tumor cells is effectively improved, and the composition has huge potential and application prospects for subsequent drug screening.

The invention relates to a novel liposome polydopamine nanoparticle and application thereof in treating renal cell carcinoma. The preparation method of the nanoparticles comprises the following steps: adding liposome into si-circPVT1 dissolved in ribonuclease-free water, and carrying out vortex mixing to form a si-circPVT1 liposome suspension; dispersing the dopamine PDA modified liposome into a Tris-HCl solution, then adding dopamine hydrochloride, and stirring to obtain dopamine PDA modified liposome; then dispersing in a streptavidin solution, and fully oscillating at 4 DEG C under a dark condition to obtain a compound; and mixing the complex with a biotin-labeled MUC12 antibody solution for incubation, and washing the obtained suspension with a PBS (Phosphate Buffer Solution) to obtain the novel liposome polydopamine nanoparticles marked as SCLPM-NPs. The product prepared by the invention realizes targeted delivery of kidney cell cancer cell lines, and the SCLPM-NPs can effectively target tumor tissue parts and inhibit the growth of kidney tumors.

The invention discloses an application of sanguinarine chloride (SGC) in preparation of a medicine for treating a PRCC-TFE3 rearranged renal cell carcinoma (rRCC), and belongs to the technical field of biological medicine, in particular to an application of sanguinarine chloride (SGC) in preparation of a medicine for treating a PRCC-TFE3 rearranged renal cell carcinoma (rRCC). According to the application, it is found for the first time that SGC has a specific killing effect on PRCC-TFE3 rRCC cells and has extremely low toxicity on normal kidney cells; the SGC has multiple anti-tumor action mechanisms: on one hand, the SGC is directly combined with and antagonizes a VEGFR2 receptor on a cell membrane to block autocrine signal transduction of VEGFB; on the other hand, the SGC inhibits transcription of VEGFB (vascular endothelial growth factor B) through ROS / p-STAT3 axis epigenetics; besides, the SGC can inhibit the production of lactic acid and the acylation of H3K18, and down-regulate the secretion of chemotactic factors, so that the infiltration of polymorphic myeloid-derived suppressor cells (PMN-MDSCs) in a tumor microenvironment is remarkably inhibited; in an immune sound mouse model, the SGC shows an excellent in-vivo anti-tumor effect, and a brand new targeting and immunoregulation double-effect candidate drug is provided for clinically treating the PRCC-TFE3 rRCC lacking an effective standard therapy.

The present application belongs to the technical field of biological medicine, and relates to a gene therapy preparation for treating drug-resistant renal cell carcinoma as well as a preparation method and application thereof. It is found for the first time that UBL3 is a key gene for mediating cross-resistance of VEGFR inhibitors of renal cancer, and a lipid nanoparticle composite system integrating specific gene editing and active targeted delivery functions is constructed based on this. The preparation can effectively restore the sensitivity of drug-resistant tumors to first-line drugs such as sunitinib, and shows a significant anticancer effect in in-vivo and in-vitro models, and has important clinical transformation value.

The application discloses application of a substance for reducing PLOD2 protein content or activity in sarcomatoid renal cell carcinoma treatment and belongs to the biomedical field. The application finds that by inhibiting PLOD2 protein content or activity in sarcomatoid renal cell carcinoma, low-differentiation, high-malignancy, highly-treatment-resistant sarcomatoid renal cell carcinoma is induced to differentiate into high-differentiation, low-malignancy, high-treatment-sensitive epithelioid renal cell carcinoma, so that the treatment purpose is achieved. The substance for reducing PLOD2 protein content or activity can not only be used for the separate treatment of sarcomatoid renal cell carcinoma, but also can be used in combination with traditional renal cancer drugs to improve the sensitivity of the traditional renal cancer drugs. At present, there is no clear and effective treatment method for sarcomatoid renal cell carcinoma, and the survival period of most patients is less than 1 year. The application provides a brand-new treatment strategy and intervention target for sarcomatoid renal cell carcinoma patients and has an important clinical application prospect.

The present application relates to the technical field of medical image analysis and gene detection, in particular to a cell-level pathological feature and gene mutation data matching model construction method, a cell-level pathological feature and gene mutation data matching model and application thereof. The present application realizes cell-level pathological feature extraction of pathological images and precise correlation analysis of gene mutations by combining high-resolution pathological image analysis and single-cell gene mutation sequencing technology. This innovation not only improves the accuracy and comprehensiveness of pathological diagnosis, but also provides more rich lesion information for clinicians, which helps to develop more personalized treatment plans. Through comprehensive analysis of pathological features such as cell morphology, nucleolus features and chromatin distribution and gene mutation data, a new way for precise medical treatment of renal cell carcinoma is further opened up, which has important clinical application value and social significance.

The invention provides a method and a model for predicting the risk of early renal function decline after renal partial resection of a renal cell carcinoma patient. According to the method, clinical parameters of a patient are obtained through a preoperative nomogram or preoperative-intraoperative combined nomogram prediction model, risk integrals of all the parameters are distributed, a total integral is calculated, and the postoperative early renal function decline prediction probability is determined and visually output. The parameters of the preoperative nomogram prediction model comprise age, diabetes history, preoperative estimated glomerular filtration rate, kidney score and radiomics score; the joint model newly increases the intra-operative ischemia time. Model construction comprises the steps of CT image standardization, region segmentation, radiology feature extraction and preprocessing and the like, and can assist in clinical accurate assessment of risks and optimization of treatment decisions.

The present application relates to the technical field of image processing, and especially relates to a renal cell carcinoma atypia intelligent identification and subtype classification method based on deep learning. The present application inputs a renal cell image into a deep learning subtype classification model, obtains image network features, and obtains network features of cells in the renal cell image; morphological nuclear features and texture features of cells in the renal cell image are extracted, cells are graded by using different features in the morphological nuclear features, and an overlapping cell set between adjacent grades, a morphological nuclear feature overlapping degree and an overlapping feature area distinguishing degree are determined; based on the morphological nuclear feature overlapping degree and the texture features of cells in the overlapping cell set, network features of cells in the overlapping cell set are enhanced, enhanced network features are obtained, and atypia identification and subtype classification of cells are performed. The present application optimizes and enhances network features of cells with high overlapping degrees, and effectively improves the accuracy of cell atypia identification and subtype classification.

The application provides a kind of prediction method and model of early renal function decline risk of renal cell carcinoma patient after partial nephrectomy.Methods obtain patient clinical parameters by preoperative nomogram or preoperative-intraoperative joint nomogram prediction model, assign each parameter risk score and calculate total score, determine the prediction probability of early postoperative renal function decline and can be visualized output.Preoperative nomogram prediction model parameters include age, history of diabetes, preoperative estimated glomerular filtration rate, kidney score and radiomics score;Intraoperative ischemia time is added to the joint model.Model construction is standardized by CT image, region segmentation, radiology feature extraction and preprocessing, etc., which can assist clinical precise risk assessment and optimize treatment decision.

The application relates to the technical field of tumor treatment, and particularly discloses application of NOSIP in preparation of a drug for treating renal cell carcinoma, and provides small interfering RNA (siRNA) for interfering with NOSIP expression, a target sequence of which is shown in SEQ ID No. 1 and / or SEQ ID No. 2. The application proves that NOSIP can promote proliferation, migration, invasion and angiogenesis of renal cell carcinoma cells, and is a key factor for driving malignant progression of renal cell carcinoma. By knocking down NOSIP expression through specific siRNA, the proliferation capacity, migration capacity, invasion capacity and angiogenesis capacity of renal cell carcinoma cells can be significantly inhibited. The application provides a new molecular target and candidate drug for treatment of renal cell carcinoma, and can be used for preparing a drug for treating renal cell carcinoma, inhibiting proliferation, migration and angiogenesis of renal cell carcinoma.

The invention discloses a targeted drug for sensitizing Ilismos-copper complex induced copper death and application thereof, can sensitize copper death induced by tumor cells to Cu (II)-Elesclomol, and realizes high-efficiency and low-toxicity treatment of renal cell carcinoma in combination with a c-Met targeting technology, and particularly relates to a targeted drug for sensitizing Ilismos-copper complex induced copper death and application thereof. According to the targeted drug for sensitizing the ilisterim-copper complex to induce copper death, mesoporous silica serves as a nano-carrier, the surface of the carrier is modified with specific polypeptide of a targeted kidney cancer cell c-Met receptor, and taurine and a Cu (II)-Elesclomol complex are jointly loaded in an internal pore channel of the carrier.

This disclosure describes bispecific antibodies targeting human programmed death-1 (PD-1) and human transforming growth factor β receptor 2 (TGFβR2) for use in the treatment of disorders such as non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), squamous cell carcinoma of the cervix and adenocarcinoma of the cervix (CESC), ovarian cancer, breast cancer, bladder cancer, renal cell carcinoma, melanoma, gastric adenocarcinoma, esophageal cancer, gastroesophageal adenocarcinoma, malignant pleural mesothelioma, pancreatic adenocarcinoma, and colorectal cancer (CRC).

The present application relates to the technical field of renal cell carcinoma, and particularly relates to a method for predicting the lipid metabolism regulation mechanism of renal cell carcinoma, which is characterized by the following steps: determining the expression difference of EMT, cell proliferation and apoptosis proteins in groups through molecular detection, and determining the difference of fat pathway genes, oil accumulation degree and fat factor expression level in groups, and determining the correlation between lipid metabolism and GAD2, the present project first proposes the miR-metabolic enzyme-lipid pool regulation axis, which is different from the traditional mode of miR directly targeting proliferation genes. Previous studies have focused on the regulation of miRNA on directly related genes such as tumor cell proliferation and apoptosis, and the present project starts from the fat metabolism pathway and deeply explores the regulation of miR-362-5p targeting GAD2 gene on the progression of renal cell carcinoma (RCC). This innovation provides a new perspective and theoretical framework for RCC research, and is expected to open up a new treatment idea, and a systematic research system from clinical samples, cell experiments, molecular detection to animal experiments is constructed.

The application relates to the field of biological medicine, in particular to a human renal clear cell carcinoma high-metastasis cell line, which is classified and named as human renal clear cell carcinoma high-metastasis cell 786O-M2-Luc Homo sapiens, and the preservation number is CCTCC No: C2025339. The renal clear cell carcinoma high-metastasis cell line can be applied to constructing a renal clear cell carcinoma high-metastasis cell model or an animal model. The cell line of the application can form a stable orthotopic tumor in an immunodeficient mouse, can cause distant organ metastasis such as lung metastasis, can express a GFP and Luciferase double-reporting system, and is convenient for in-vitro sorting and in-vivo IVIS imaging tracking. The cell line of the application retains the typical renal cell carcinoma characteristics of 786-O cells in vitro, but has stronger proliferation, migration and invasion capacity, and can be used as a tool model for renal cancer metastasis mechanism research and drug screening.

This invention discloses the application of reagents for detecting REEP protein in the preparation of products for diagnosing prostate cancer, relating to the field of biomedical technology. Through proteomic analysis, ELISA assays, and immunohistochemical analysis of urinary proteins from prostate cancer patients, clear cell renal cell carcinoma patients, urothelial carcinoma patients, and healthy individuals, as well as paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue, urothelial carcinoma tissue, and clear cell renal cell carcinoma tissue, it was found that REEP6 and REEP5 proteins are related to the occurrence and development of prostate cancer and can be used to assist in the diagnosis of prostate cancer. Furthermore, in urinary testing, REEP6 and REEP5 have higher sensitivity compared to PSA, and the three proteins can complement each other, thus helping to improve the diagnostic rate and non-invasive screening capabilities. Research on the relationship between REEP6 and REEP5 proteins and prostate cancer facilitates non-invasive follow-up after treatment and guides medication, thereby improving survival rates.